Elevated tissue inhibitor of metalloproteinase-1 along with left atrium hypertrophy predict atrial fibrillation recurrence after catheter ablation
This study aimed to establish a model that predicts atrial fibrillation (AF) recurrence after catheter ablation using clinical risk factors and biomarkers. We used a prospective cohort study, including 230 consecutive persistent AF patients successfully treated with catheter ablation from January 20...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.1010443/full |
| _version_ | 1811246888382365696 |
|---|---|
| author | Weiping Sun Weiping Sun Haiwei Li Zefeng Wang Qin Li Haichu Wen Yongquan Wu Jie Du Jie Du |
| author_facet | Weiping Sun Weiping Sun Haiwei Li Zefeng Wang Qin Li Haichu Wen Yongquan Wu Jie Du Jie Du |
| author_sort | Weiping Sun |
| collection | DOAJ |
| description | This study aimed to establish a model that predicts atrial fibrillation (AF) recurrence after catheter ablation using clinical risk factors and biomarkers. We used a prospective cohort study, including 230 consecutive persistent AF patients successfully treated with catheter ablation from January 2019 to December 2020 in our hospital. AF recurrence was followed-up after catheter ablation, and clinical risk factors and biomarkers for AF recurrence were analyzed. AF recurred after radiofrequency ablation in 72 (31%) patients. Multiple multivariate logistic regression analysis demonstrated that tissue inhibitor of metalloproteinase-1 (TIMP-1) and left atrium diameter (LAd) were closely associated with AF recurrence. The prediction model constructed by combining TIMP-1 and LAd effectively predicted AF recurrence. Additionally, the model’s performance discrimination, accuracy, and calibration were confirmed through internal validation using bootstrap resampling (1,000 times). The model showed good fitting (Hosmer–Lemeshow goodness chi-square 3.76138, p = 0.926) and had a superior discrimination ability (the area under the receiver operation characteristic curve0.917; 95% CI 0.882–0.952). The calibration curve showed good agreement between the predicted probability and the actual probability. Moreover, the decision curve analysis (DCA) showed the clinical useful of the nomogram. In conclusion, our predictive model based on serum TIMP-1 and LAd levels could predict AF recurrence after catheter ablation. |
| first_indexed | 2024-04-12T15:00:55Z |
| format | Article |
| id | doaj.art-65ddc9a59df74247bd3835075f2e213f |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-12T15:00:55Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-65ddc9a59df74247bd3835075f2e213f2022-12-22T03:28:05ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-11-01910.3389/fcvm.2022.10104431010443Elevated tissue inhibitor of metalloproteinase-1 along with left atrium hypertrophy predict atrial fibrillation recurrence after catheter ablationWeiping Sun0Weiping Sun1Haiwei Li2Zefeng Wang3Qin Li4Haichu Wen5Yongquan Wu6Jie Du7Jie Du8Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, ChinaBeijing Institute of Heart Lung and Blood Vessel Disease, Beijing, ChinaDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, ChinaDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, ChinaBeijing Institute of Heart Lung and Blood Vessel Disease, Beijing, ChinaBeijing Institute of Heart Lung and Blood Vessel Disease, Beijing, ChinaDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, ChinaDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, ChinaBeijing Institute of Heart Lung and Blood Vessel Disease, Beijing, ChinaThis study aimed to establish a model that predicts atrial fibrillation (AF) recurrence after catheter ablation using clinical risk factors and biomarkers. We used a prospective cohort study, including 230 consecutive persistent AF patients successfully treated with catheter ablation from January 2019 to December 2020 in our hospital. AF recurrence was followed-up after catheter ablation, and clinical risk factors and biomarkers for AF recurrence were analyzed. AF recurred after radiofrequency ablation in 72 (31%) patients. Multiple multivariate logistic regression analysis demonstrated that tissue inhibitor of metalloproteinase-1 (TIMP-1) and left atrium diameter (LAd) were closely associated with AF recurrence. The prediction model constructed by combining TIMP-1 and LAd effectively predicted AF recurrence. Additionally, the model’s performance discrimination, accuracy, and calibration were confirmed through internal validation using bootstrap resampling (1,000 times). The model showed good fitting (Hosmer–Lemeshow goodness chi-square 3.76138, p = 0.926) and had a superior discrimination ability (the area under the receiver operation characteristic curve0.917; 95% CI 0.882–0.952). The calibration curve showed good agreement between the predicted probability and the actual probability. Moreover, the decision curve analysis (DCA) showed the clinical useful of the nomogram. In conclusion, our predictive model based on serum TIMP-1 and LAd levels could predict AF recurrence after catheter ablation.https://www.frontiersin.org/articles/10.3389/fcvm.2022.1010443/fullatrial fibrillationbiomarkersTIMP metallopeptidase inhibitor 1recurrenceleft atrium diameter |
| spellingShingle | Weiping Sun Weiping Sun Haiwei Li Zefeng Wang Qin Li Haichu Wen Yongquan Wu Jie Du Jie Du Elevated tissue inhibitor of metalloproteinase-1 along with left atrium hypertrophy predict atrial fibrillation recurrence after catheter ablation Frontiers in Cardiovascular Medicine atrial fibrillation biomarkers TIMP metallopeptidase inhibitor 1 recurrence left atrium diameter |
| title | Elevated tissue inhibitor of metalloproteinase-1 along with left atrium hypertrophy predict atrial fibrillation recurrence after catheter ablation |
| title_full | Elevated tissue inhibitor of metalloproteinase-1 along with left atrium hypertrophy predict atrial fibrillation recurrence after catheter ablation |
| title_fullStr | Elevated tissue inhibitor of metalloproteinase-1 along with left atrium hypertrophy predict atrial fibrillation recurrence after catheter ablation |
| title_full_unstemmed | Elevated tissue inhibitor of metalloproteinase-1 along with left atrium hypertrophy predict atrial fibrillation recurrence after catheter ablation |
| title_short | Elevated tissue inhibitor of metalloproteinase-1 along with left atrium hypertrophy predict atrial fibrillation recurrence after catheter ablation |
| title_sort | elevated tissue inhibitor of metalloproteinase 1 along with left atrium hypertrophy predict atrial fibrillation recurrence after catheter ablation |
| topic | atrial fibrillation biomarkers TIMP metallopeptidase inhibitor 1 recurrence left atrium diameter |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2022.1010443/full |
| work_keys_str_mv | AT weipingsun elevatedtissueinhibitorofmetalloproteinase1alongwithleftatriumhypertrophypredictatrialfibrillationrecurrenceaftercatheterablation AT weipingsun elevatedtissueinhibitorofmetalloproteinase1alongwithleftatriumhypertrophypredictatrialfibrillationrecurrenceaftercatheterablation AT haiweili elevatedtissueinhibitorofmetalloproteinase1alongwithleftatriumhypertrophypredictatrialfibrillationrecurrenceaftercatheterablation AT zefengwang elevatedtissueinhibitorofmetalloproteinase1alongwithleftatriumhypertrophypredictatrialfibrillationrecurrenceaftercatheterablation AT qinli elevatedtissueinhibitorofmetalloproteinase1alongwithleftatriumhypertrophypredictatrialfibrillationrecurrenceaftercatheterablation AT haichuwen elevatedtissueinhibitorofmetalloproteinase1alongwithleftatriumhypertrophypredictatrialfibrillationrecurrenceaftercatheterablation AT yongquanwu elevatedtissueinhibitorofmetalloproteinase1alongwithleftatriumhypertrophypredictatrialfibrillationrecurrenceaftercatheterablation AT jiedu elevatedtissueinhibitorofmetalloproteinase1alongwithleftatriumhypertrophypredictatrialfibrillationrecurrenceaftercatheterablation AT jiedu elevatedtissueinhibitorofmetalloproteinase1alongwithleftatriumhypertrophypredictatrialfibrillationrecurrenceaftercatheterablation |